Biogen gave the Alzheimer’s field something real to argue about this week, and the argument is worth having.
At the Alzheimer’s Association International Conference, the company presented what BioSpace called an unprecedented drop in tau—the tangled protein that many researchers believe drives the actual cognitive decline in Alzheimer’s, distinct from the amyloid plaques that dominated drug development for twenty years. That is genuine validation for the anti tau approach, and it supports Biogen’s controversial decision to push diranersen into Phase 3 even though the drug missed its primary endpoint in Phase 2.
But the market did not buy it. Biogen shares fell 8% after a fuller look at the mid stage data renewed the obvious question: if you missed the endpoint that measures whether patients actually did better, how much does a biomarker win really tell you? And is there a dosing problem underneath the mixed result?
Both things are true at once. The science took a step forward. The clinical case stayed murky. That is Alzheimer’s in a sentence.
Separately, Celcuity turned a rough June into its first FDA approval. Q2 earnings season opens with the sector in its best shape in years. A China origin melanoma drug hit Phase 3 the day before the congressional deadline. And Chai Discovery raised $400 million for AI molecular design.
Biogen’s Tau Data: Unprecedented Science, Unresolved Clinical Questions
What Happened: Biogen presented Phase 2 data for diranersen at the Alzheimer’s Association International Conference showing an unprecedented reduction in tau protein. The drug missed its primary clinical endpoint. Shares fell 8%.
Why Tau Matters More Than Most People Realize
For two decades, Alzheimer’s drug development was dominated by the amyloid hypothesis—the idea that clearing the sticky amyloid plaques that accumulate between neurons would slow or stop the disease. Billions of dollars were spent. Nearly every program failed. The drugs that finally did clear amyloid—including Biogen’s own Leqembi, developed with Eisai—delivered modest benefit at best. Clear the plaques, and patients still decline. Just a little slower.
Tau is the other half of Alzheimer’s biology, and many researchers have long believed it is the more important half. While amyloid accumulates between neurons, tau tangles form inside neurons, and their spread through the brain correlates more tightly with the actual cognitive decline that patients and families experience. The hypothesis: if you can stop tau from tangling and spreading, you address the part of the disease that actually destroys thinking and memory, not just the part that shows up on a brain scan.
Biogen showing an unprecedented reduction in tau with diranersen is meaningful because it proves the tau target is drug addressable. You can get a drug into the brain, have it engage the tau protein, and dramatically reduce the amount of pathological tau present. That has not been demonstrated at this magnitude before. It validates not just diranersen but the entire anti tau field.
Why the Market Still Punished Biogen
The 8% stock drop tells you something important about where investor sentiment sits on Alzheimer’s drugs. The market has been burned too many times to celebrate a biomarker without a clinical result.
A biomarker is not a clinical outcome. Lowering tau is a laboratory measurement. The primary endpoint that diranersen missed was the measurement that matters to patients: did they think more clearly, remember more reliably, function better in daily life? Biogen’s argument for proceeding to Phase 3 despite the miss is that the biomarker reduction was so dramatic that the clinical benefit should follow, possibly at a different dose or with a longer treatment duration. That is a reasonable scientific hypothesis. It is also exactly the kind of bet that has gone wrong repeatedly in Alzheimer’s history, where promising biological signals have failed to translate into meaningful patient benefit over and over again.
The dosing question makes it harder. If the Phase 2 data show a signal of benefit at some dose levels but not others, it suggests the Phase 2 design may not have optimized the drug’s exposure. Going to Phase 3 with that uncertainty means Biogen is betting it can find the right dose in the larger trial, which adds another layer of risk to a program that already carries the fundamental uncertainty of whether lowering tau translates into better cognition.
What This Means for “The New Biogen”
This is the defining bet of Biogen’s neuroscience pivot. We have covered “the new Biogen” since the company announced its partnership driven strategy in June, followed by the $1 billion RayThera acquisition for immunology, the felzartamab consolidation ($850 million), and the salanersen Breakthrough Therapy for SMA. The company has been building aggressively across multiple fronts.
But diranersen in Alzheimer’s is the one that could define the decade. Alzheimer’s is the largest neuroscience market. If Phase 3 succeeds, Biogen has a genuinely differentiated drug targeting the mechanism most researchers believe matters most, in a disease that affects millions. If it fails, Biogen loses its most important pipeline bet and the skeptics who questioned the Phase 3 decision based on the missed endpoint will have been proven right.
There is not much middle ground. The tau field took a step forward this week. Whether diranersen specifically took a step forward is what Phase 3 will answer.
Celcuity Turned a Rocky June Into Its First Approval
What Happened: The FDA approved Celcuity’s Revtorpyk (gedatolisib) for adults with hormone receptor positive, HER2 negative advanced breast cancer without a PIK3CA mutation, after progression on endocrine therapy.
The Same Drug, a Different Story Than June
This is the drug we covered in June when it doubled progression free survival but saw its stock drop 25% on questions about the magnitude of benefit and the competitive landscape. The market looked at the data, decided the win was not big enough, and sold.
The FDA looked at the same data and approved the drug. That disconnect—a rough market reaction to a data readout and the ultimate regulatory and commercial value of a drug—is worth remembering. Stock reactions on the day of a clinical readout are driven by expectations, positioning, and the mood of the moment. Regulatory decisions are driven by the totality of the evidence evaluated over months. The two do not always agree, and when they diverge, the regulatory decision is the one that determines whether patients get the drug.
Why the Wild Type Positioning Matters
The approval is specifically for patients without a PIK3CA mutation. That distinction is important. In HR positive, HER2 negative breast cancer, a significant share of patients carry PIK3CA mutations, and several existing drugs target that population specifically. It is a crowded, well served segment. The patients without the mutation—the wild type population—have historically had fewer targeted options after they progress on endocrine therapy.
By landing in the wild type setting, Celcuity avoids competing directly against the established mutation targeted drugs and instead addresses a population with real unmet need. Gedatolisib works here because it hits multiple nodes of the PI3K pathway rather than targeting a single specific mutation, which is what lets it benefit patients regardless of their PIK3CA status.
Fierce Biotech noted Revtorpyk is also in development for prostate cancer and other solid tumors, with multibillion dollar sales potential if those pan out. For a company landing its first ever FDA approval, establishing the drug in an underserved niche and then expanding into larger indications is exactly the kind of trajectory that builds a franchise.
Q2 Earnings Open With the Wind at Pharma’s Back
Biopharma enters Q2 earnings season riding dealmaking, venture flow, and a clearing of regulatory overhangs. BioSpace reported the sector is in its best shape in years, and the numbers support it.
The IPO market has already eclipsed all of 2025, with Attovia filing this week for an IPO to fund a potential Dupixent challenger and Braveheart Bio heading for Nasdaq to push a Phase 3 cardiovascular drug. After four years in the wilderness—the 2022 biotech crash, frozen IPO markets, and two years of brutal layoffs—the sector is genuinely healthier.
Management teams on the Q2 calls will lean into the tailwinds: the record M&A wave ($134 billion plus across 33 deals over $1 billion), the friendlier FDA posture under acting leadership, and easing policy uncertainty. For Lilly, the questions will be about retatrutide’s two pivotal wins, the Medicare Bridge uptake, and how 14 deals integrate. For Novo, the MASH approval and oral Wegovy positioning. For AbbVie, the Apogee close and zumilokibart development timeline. For Merck, sac TMT filing plans and the post Keytruda strategy. For Pfizer, the Padcev perioperative expansion and the Seagen pipeline beyond it.
The one caveat we keep flagging: the money is pooling at the late stage and commercial end while early stage stays starved. Two thirds of venture money went to clinical stage companies. Early stage venture is at its lowest in years. The tailwinds are real, but they are not blowing evenly. The executives celebrating healthy markets this quarter are drawing down an inventory of clinical stage assets that was funded years ago. Whether the next generation of that inventory is being funded adequately is the question nobody will volunteer on an earnings call.
Another China Drug Delivered, One Day Before the Deadline
What Happened: HUYABIO International said HBI 8000 combined with BMS’s Opdivo met its primary endpoint in a Phase 3 trial in advanced melanoma. HBI 8000 is a drug HUYABIO licensed out of China.
The Timing Could Not Be More Perfect
Tomorrow is July 17. The five named pharma companies—Merck, AbbVie, Lilly, Pfizer, and BMS—must submit their responses to the House Select Committee on China. And the day before the deadline, the China pipeline delivers another Phase 3 win.
This is the tension the entire debate turns on. The political case for restricting China engagement keeps running into the clinical case for continuing it, and the clinical case keeps posting positive data. Hansoh’s GSK partnered ADC hit its OS endpoint in small cell lung cancer earlier this week. Kailera’s oral obesity drug won in China last week. AstraZeneca paid $600 million upfront for an approved Chinese lung cancer drug on Wednesday. And now HBI 8000 plus Opdivo met its Phase 3 endpoint in melanoma.
Every positive readout from a Chinese asset makes the industry’s argument stronger: the science is real, the patients benefit, and restricting access to Chinese innovation would harm American drug development. Every congressional letter, every pending bill, every political headline makes the counter argument: the speed and cost advantages come with national security risks that the industry has not adequately addressed.
We will cover the deadline and what the five companies say in tomorrow’s edition. The setup could not be more on point. The science delivered today. The politics arrive tomorrow.
Chai Discovery Raises $400M for AI Molecular Design
What Happened: AI drug discovery firm Chai Discovery raised $400 million in a Series C at a $3.8 billion valuation to expand its molecular design platform across the industry.
Why This Matters: The raise continues the steady flow of large AI discovery financings we have tracked all year—Isomorphic Labs ($2.7 billion total funding), Insilico/SK ($2.5 billion), Lilly/Profluent ($2.25 billion), and the broader Anthropic pharma ecosystem. Notably, the Chai raise lands the same week that Anthropic’s own CEO counseled patience on how fast AI will change biology. The capital is not slowing even as the loudest voices temper expectations.
That disconnect is healthy. It means the investors putting $400 million into Chai at a $3.8 billion valuation are making a long term bet on the technology’s value rather than chasing short term hype. AI molecular design—using computational models to predict which molecules will bind targets, how they will behave in the body, and which will make it through development—is a genuine capability that accelerates the discovery phase of drug development. The question has never been whether AI works for this purpose (it does) but whether the timelines the hype cycle promised were realistic (they were not). Amodei saying so, and investors continuing to fund the technology anyway, suggests the field is maturing past the hype phase and into the value phase.
Strategic Themes
1. Biogen’s Tau Data Split the Science from the Stock, and Both Sides Have a Point
The unprecedented tau reduction validates the anti tau approach. The missed primary endpoint and dosing questions validate the market’s skepticism. Alzheimer’s has humbled every company and every mechanism that has tried it. Biogen deserves credit for pursuing tau when the field was fixated on amyloid, and for showing that the target can be hit at a meaningful magnitude. But the market has seen too many biomarker wins fail to become patient wins to price in the Phase 3 before the data arrive. The Phase 3 will settle it. Until then, both the enthusiasm and the skepticism are reasonable.
2. Celcuity’s Approval Proves That Market Reactions and Regulatory Outcomes Are Different Things
Stock down 25% on the data readout in June. FDA approval in July. The lesson is not that the market was wrong about the data—the questions about magnitude were fair. The lesson is that a drug’s commercial trajectory is determined by its regulatory path, its clinical utility for underserved patients, and its expansion potential, not by the first day’s stock reaction. Celcuity now has an approved drug, a wild type breast cancer niche with real unmet need, and a development path into prostate cancer and other tumors. The 25% drop looks different in that context.
3. The China Pipeline Delivered Again on the Eve of the Deadline
HBI 8000 plus Opdivo in melanoma. Hansoh’s ADC in SCLC earlier this week. Kailera’s oral obesity drug last week. AstraZeneca’s $600 million Dizal deal on Wednesday. The data keep arriving, and they keep being positive. Tomorrow the five named companies submit their responses to the House Select Committee. The industry’s real answer has been written in clinical data and wire transfers all week. The formal letters are a legal obligation. The deals are the strategic conviction.
4. $400M for AI Molecular Design at a $3.8B Valuation Says the Technology Has Matured Past the Hype
When the CEO of one of the leading AI companies tempers expectations and a $400 million Series C still closes at a nearly $4 billion valuation, the market is telling you it has separated the hype from the technology. AI in drug discovery is no longer being funded on the promise that it will revolutionize everything overnight. It is being funded on the evidence that it genuinely accelerates specific parts of the process, and that the returns, while slower than the early pitches suggested, are worth the investment at scale.
Frequently Asked Questions
What did Biogen’s tau data show?
An unprecedented reduction in tau protein with diranersen at the Alzheimer’s Association International Conference. But the drug missed its primary clinical endpoint in Phase 2. Biogen is advancing to Phase 3 anyway, betting that the biomarker win will translate to clinical benefit at the right dose. Shares fell 8%.
What is Celcuity’s Revtorpyk?
Gedatolisib, approved for HR positive HER2 negative advanced breast cancer without a PIK3CA mutation. The drug doubled PFS in Phase 3. First FDA approval for Celcuity. Multibillion dollar potential if prostate cancer and other solid tumor indications are confirmed.
What is the China deadline?
Tomorrow, July 17. Merck, AbbVie, Lilly, Pfizer, and BMS must respond to the House Select Committee on China with details on data protection, ethics, and oversight at Chinese trial sites. One more China drug hit Phase 3 today, the day before the deadline.
How are the capital markets?
Q2 earnings season opens with the sector in its best shape in years. IPOs have eclipsed all of 2025. M&A exceeds $134 billion. Venture is flowing at the late stage. But early stage remains starved, and the barbell shape of financing is a structural concern for the pipeline five to ten years from now.
What is Chai Discovery?
An AI molecular design company that raised $400 million in a Series C at a $3.8 billion valuation. The raise continues the AI drug discovery capital wave alongside Isomorphic, Insilico, and the Anthropic ecosystem.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Biogen’s Tau Bet. We analyze what the biomarker actually tells you versus what it does not, whether the Phase 3 bet is defensible given the missed endpoint and dosing questions, and how to think about the risk profile of Biogen’s most important pipeline asset.
Celcuity’s Wild Type Niche. We explain why the PIK3CA wild type positioning could be worth more than the mutation positive market that most competitors target, and how the expansion path into prostate cancer and other tumors changes the franchise valuation.
Q2 Earnings Preview. We identify what to listen for across the major pharma calls—capital allocation intentions, China exposure framing, and GLP 1 franchise math—and flag the quiet risk that nobody will volunteer but that matters most for the 2030s pipeline.
Plus: HUYABIO/Opdivo melanoma Phase 3, Chai Discovery AI raise, July 17 deadline coverage plan, Section 232 countdown (15 days), and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
